恩替卡韦联合免疫制剂治疗免疫耐受期乙型肝炎病毒携带者疗效探讨

doi:10.3969/j.issn.1672-5069.2016.01.007

摘要/Abstract

摘要： 目的观察恩替卡韦联合免疫制剂治疗免疫耐受期乙型肝炎病毒（HBV）携带者的临床疗效。方法按就诊顺序编号将66例HBV携带者随机分为治疗组33例和对照组33例。给予治疗组恩替卡韦联合重组乙肝疫苗（CHO细胞）20 μg、重组人白细胞介素-II 20万单位和重组人粒细胞集落刺激因子75 μg三角肌皮下注射,1次/m,疗程为3年;对照组只接受单纯的恩替卡韦治疗,疗程也为3年。治疗前后常规检测血清丙氨酸氨基转移酶（ALT）、HBV DNA、血清HBV标记物的变化。结果在治疗结束时,治疗组患者血清HBeAg阴转率、HBeAg血清转换率和HBV DNA阴转率分别为33.3%、24.2％和75.7%,显著高于对照组的12.1%、6.0%和51.5% （P<0.05）;在治疗结束后6个月时,治疗组血清HBeAg阴转率、HBeAg血清转换率和HBV DNA阴转率分别为42.3%、27.2%和78.7%,也显著高于对照组的12.1%、6.0%和45.4% （P<0.05）;在治疗过程中两组部分患者ALT升高,其中治疗组为42.3%,显著高于对照组的9.0%（P<0.05）。结论核苷类药物联合免疫制剂治疗HBV携带者,在部分人群能打破免疫耐受,并获得病毒学清除。

关键词: 乙型肝炎病毒携带者, 免疫耐受, 恩替卡韦, 免疫疗法

Abstract: Objective To observe the clinical efficacy of combination of entecavir（ETV） and immunotherapy in the treatment of hepatitis B virus carriers. Method 66 hepatitis B virus carriers were randomly assigned into treatment group and control group with 33 in each group. Individuals in the treatment group were treated by ETV and hepatitis B vaccine,rIL-2,and G-CSF,and those in the control group were treated with ETV alone. The regimen lasted for three years in both groups. Before and after the treatment,serum level of ALT,HBV DNA,HBeAg,HBeAb,HBsAg were detected routinely. Results At the end of the treatment,negative rate of serum HBeAg in the treatment group was 33.3%,significantly higher than that in the control group（12.1%,P<0.05）;the seroconversion rate of HBeAg to anti-HBe was 24.2% in the treatment group,significantly higher than that in the controls（6.0%,P<0.05）;the serum HBV DNA loss in treatment group was 75.7%,significant higher than that in the control group（51.5%,P<0.05）;At the end of six months after the discontinuation of the treatment,the negative rate of serum HbeAg was 42.4%,the seroconversion of HbeAg to anti-HBe rate was 27.2%,and the serum HBV DNA loss was 78.7% in the treatment group,all significantly higher than those in the controls（12.1%,6.0% and 45.4%,respectively,P<0.05）;serum levels of ALT were elevated in 42.3% of individuals in treatment group, significantly higher than that in the controls（9.0%,P<0.05）. Conclusion The clinical efficacy of combination therapy with nucleoside analogues and immune-modulating agents are promising,which might break the state of immune tolerance in some hepatitis B virus carriers.

Key words: Hepatitis B virus carriers, Entecavir, Immune tolerance, Immune-modulating agents

赵和平, 侯田青, 丁保华, 张自然, 李靖, 刘晓蕾, 邵丹丹, 郭世民. 恩替卡韦联合免疫制剂治疗免疫耐受期乙型肝炎病毒携带者疗效探讨[J]. 实用肝脏病杂志, 2016, 19(1): 25-28.

Zhao Heping, Hou Tianqing, Ding Baohua, Zhang Ziran, Li jing, Liu Xiaolei, ShaoDandan, Guo Shimin. Efficacy of entecavir and immunotherapy in treatment of hepatitis B virus carriers[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 25-28.

参考文献

[1] 李志刚．103 例乙型肝炎免疫耐受期患者抗病毒的疗效分析．中国实用医药,2011,24：17-18．
[2] 李嘉,赵桂鸣,李颖．免疫耐受期慢性乙型肝炎病毒感染者临床与肝脏病理学特点．中华传染病杂志,2008,26：662-665．
[3] Strader DB,Wright T,Thomas DL,et al. Diagnosis,management and treatment of hepatitis C. Hepatology,2004,39:1147-1171.
[4] Seeger C,Mason W. Hepatitis B virus biology. Microbiol Mol Biol Rev,2000,64:51-68.
[5] 武琼,刘娜,徐光华. 慢性乙型肝炎免疫耐受期的新认识. 肝脏,2014,19（2）:154–156.
[6] Leung N．Treatment of HBeAg-positive chronic hepatitis B with nucleos（t）ideanalogues．Liver Int,2011,31（Suppl 1）：85-89．
[7] Chen Y,Li X,Ye B,et a1．Effect of telbivudine therapy on the cellular immnune response in chronic hepatitis B．Antiviral Res,2011,91：23-31．
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[9] 王秀娟,高歌. 干扰素联合胸腺肽α1治疗免疫耐受期乙肝病毒携带者的疗效观察. 吉林医学,2005,26（4）：361–362.
[10] 赵英杰,范希成．慢性乙型肝炎抗病毒治疗的进展．寄生虫病及感染性疾病,2004,2（1）：34.
[11] 王斌. 肝炎核酸疫苗的研究进展. 上海免疫学杂志,1999,19（20）：124.
[12] Wang C,Deubner H,Shuhart M,et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection．Hepatology,2005,429 （Suppl 1）:573A．
[13] 李嘉,赵桂鸣,朱理珉,等. 免疫耐受期和非活动复制期乙型肝炎病毒感染者的肝脏病理与临床特征. 中华肝脏病杂志,2007,15：326-329．
[14] 张新元,宁更献,彭霞,等．慢性HBV 携带者肝脏病理改变及其临床意义．河北医药,2007,29:65．
[15] 颜成果,姚云清,毛晓琴. 恩替卡韦治疗慢性乙型肝炎病毒携带者近期疗效观察. 中华肝脏病杂志,2014,22（12）：900-903．
[16] Carey I,D'Antiga L,Bansal S,et al．Immune and viral profile from tolerance to hepatitis B surface antigen clearance：a longitudinal study of vertically hepatitis B virus-infected children on combined therapy．J Virol,2011,85：2416‐2428.
[17] 李旭红,赖江琼,潘兴南．抗HBV特异性主动免疫治疗肝功能正常的慢性HBV感染5年随访.实用肝脏病杂志,2006,9（4）：187-188.
[18] Mancini-Bou T,Gine M. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers．Vaccine,2006,24（21）:4482-4489．
[19] Senturk H,Tabak F,Ozars R,et a1．Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection．Dig Dis Sci,2009,54（9）：2026-2030．
[20] 李旭红,潘兴南,李树青,等．抗HBV治疗性疫苗治疗HBV携带者的临床研究．解放军医学杂志,2004,29（6）：549-550．
[21] 陈贽,陈治平,郑御雄．拉米夫定联合胸腺肽加乙型肝炎疫苗治疗慢性乙型肝炎的临床观察.实用肝脏病杂志,2006,9（6）：157-158．